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We report Zika virus (ZIKV) vertical transmission in 130 infants born to PCR+mothers at the
time of the Rio de Janeiro epidemic of 2015–2016. Serum and urine collected from birth
through the first year of life were tested by quantitative reverse transcriptase polymerase
chain reaction (PCR) and/or IgM Zika MAC-ELISA. Four hundred and seven specimens are
evaluated; 161 sera tested by PCR and IgM assays, 85 urines by PCR. Sixty-five percent of
children (N= 84) are positive in at least one assay. Of 94 children tested within 3 months of
age, 70% are positive. Positivity declines to 33% after 3 months. Five children are PCR+
beyond 200 days of life. Concordance between IgM and PCR results is 52%, sensitivity 65%,
specificity 40% (positive PCR results as gold standard). IgM and serum PCR are 61% con-
cordant; serum and urine PCR 55%. Most children (65%) are clinically normal. Equal num-
bers of children with abnormal findings (29 of 45, 64%) and normal findings (55 of 85, 65%)
have positive results, p= 0.98. Earlier maternal trimester of infection is associated with
positive results (p= 0.04) but not clinical disease (p= 0.98). ZIKV vertical transmission is
frequent but laboratory confirmed infection is not necessarily associated with infant
abnormalities.
https://doi.org/10.1038/s41467-020-17331-0 OPEN
1 Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 2 David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA. 3 Biomedical Research Institute of
Southern California, Oceanside, CA 92056, USA. 4University of California, San Francisco School of Medicine, San Francisco, CA 94143, USA. 5University of
Southern California, Los Angeles, CA 90007, USA. 6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK. 7These authors contributed equally: Patrícia Brasil, Zilton Vasconcelos. ✉email: patricia.brasil33@gmail.com; knielsen@mednet.ucla.edu









In 2015, Zika virus (ZIKV) reached Rio de Janeiro, Brazil, andlocal transmission of the virus was quickly confirmed1. At thetime, our group had an ongoing study evaluating outcomes in
pregnant women who developed a rash due to arboviral infec-
tions. With the onset of the ZIKV epidemic, we established a
longitudinal cohort of pregnant women who presented with a
rash within the prior 5 days and were found to be ZIKV positive
in blood or urine by quantitative reverse transcriptase polymerase
chain reaction (QRT-PCR) at the time of presentation2. We
followed these women throughout pregnancy to delivery and
reported on pregnancy outcomes2. Subsequently we reported
outcomes of their children in the first months and years of
life, including physical findings, neurologic examinations, neu-
roimaging results, complete eye exams, hearing assessments, and
neurodevelopmental outcomes2–7.
Although all infants in this prospective Zika cohort were
exposed in utero to maternal ZIKV infection, it is difficult to
ascertain the true rate of ZIKV vertical transmission without
infant laboratory results, as the majority of ZIKV-exposed chil-
dren are not born with severe clinical features of congenital Zika
syndrome8. Amniocentesis to detect ZIKV by RT-PCR in the
amniotic fluid can confirm vertical transmission prenatally
although this procedure is uncommonly performed in Brazil7.
There is limited data on the sensitivity and specificity of testing
after birth to confirm vertical transmission. In adults, a confirmed
laboratory diagnosis of ZIKV is challenging, as there is a brief
window period where virus detection in plasma or urine occurs9.
Zika serologic testing has been further complicated in endemic
areas by the cross-reactivity between ZIKV IgG antibodies and
antibodies against dengue virus serotypes; in that scenario most
surveillance systems rely on clinical criteria to identify cases10,11.
We sought to determine the utility of molecular and serologic
testing in the diagnosis of mother-to-child-transmission of ZIKV.
We report the frequency of ZIKV PCR and ZIKV-specific IgM
detection in the serum and urine of children with confirmed pre-
natal ZIKV exposure. We also analyzed whether positive infant
results for ZIKV were associated with abnormal pediatric outcomes.
Results
Study population. Our longitudinal cohort was comprised of 244
pregnant women with confirmed ZIKV infection during preg-
nancy, of whom 223 (91.4%) had live births. Of these, 216 infants
had clinical follow-up beyond birth. In the early stages of the
ZIKV epidemic in Rio de Janeiro between September 2015 to
February 2016, ZIKV PCR and IgM detection assays were con-
sidered investigational and not diagnostic. For this reason, there
was a delay in the collection of infant specimens while IRB
approval for infant phlebotomy and urine collection was pending.
As a result, from the original cohort of 216 infants, 130 children
(60%) had blood and or urine specimens obtained for ZIKV
detection. The present report focuses on these 130 infants with
clinical follow-up with laboratory diagnostic evaluations. Table 1
reports clinical characteristics and timing of maternal infection
for all 216 children in the cohort, with results stratified by those
who received diagnostic testing and those who did not. As seen in
the table, both groups were comparable, with the exception that
untested children tended to have lower neurodevelopmental
scores in the second to third years of life and all children with
microcephaly were in the tested group.
Diagnostic testing. In total, 407 ZIKV diagnostic assays were run
in specimens obtained from 130 exposed children. These included
PCR assays in 161 serum and 85 urine samples, and 161 serum
ZIKV IgM assays, as shown in Fig. 1. In total, 84 of 130 children
(65%) had positive laboratory test results for ZIKV as seen in
Table 2. The age at the time of performance of the first Zika
diagnostic laboratory test ranged from birth to 148 days. Within
the group of children tested in the first 90 days of life (n= 94),
70% (N= 66) tested positive by at least one detection method
(39% positive by blood PCR, 48% by urine PCR, 39% by IgM).
For 78 children who were tested beyond 90 days of age, including
repeat testing, 33% were positive by any laboratory detection
method, demonstrating that sensitivity of diagnostic testing
for ZIKV dropped considerably beyond 3 months of age. This
observation was mainly due to the fact that the sensitivity of
serum detection assays (IgM and PCR) in identifying Zika
infection declined after 3 months of age (from 39 to 15% for
serum PCR and from 39 to 20% for IgM). Although fewer chil-
dren were tested by urine PCR (73 versus 109 for serum PCR),
urine was the most frequently positive detection method within
any age group (49%), followed by Zika IgM (positivity rate of
37%) and Zika PCR of serum (35%) (Table 2).
A positive ZIKV laboratory result in antenatally exposed children
was most frequently seen in the first 3 months of life (Table 2 and
Fig. 1). Nevertheless, there were rare outliers within each assay
category who tested positive beyond 200 days of age. Three children
excreted the virus in urine at ages of 6.7, 8, and 9.4 months of age;
none have developed abnormal clinical findings as of the time of
this publication (3 years of age). However, two children with
positive serum ZIKV PCR at ages 6 and 13 months were found to
have abnormal funduscopic and hearing exams, respectively.
Frequency of testing. The frequency of specimen collection is
depicted in Table 3. The majority of children were tested only
Table 1 Frequency of abnormal findings among in utero ZIKV-exposed infants according to ZIKV postnatal testing status.
All Tested infants Untested infants p-Value*
N= 216 % N= 130 % N= 86 %
Infants with any abnormal findings 78/216 36.1 45/130 34.6 33/86 38.4 p= 0.70
Structural brain abnormalities 14/140 10.0 14/113 12.4 0/27 0 p= 0.13
Complete eye exam (abnormal) 9/137 6.6 6/109 5.5 3/28 10.7 p= 0.36
Hearing assessment (abnormal) 13/114 11.4 11/91 12.1 2/23 8.7 p= 0.68
Small for gestational age 10/216 4.6 10/130 7.7 0/86 0 p= 0.01
Below average neurodevelopmenta 62/216 28.7 17/129 13.2 45/87 51.7 p < 0.001
1st Trimester maternal infection 54/216 25.0 40/130 30.7 14/86 16.3 p= 0.06
2nd Trimester maternal infection 109/21 50.5 61/130 46.9 48/86 55.8 p= 0.47
3rd Trimester maternal infection 53/216 24.5 29/130 22.3 24/86 27.9 p= 0.47
Microcephaly 8/216 3.7 8/130 6.1 0/86 0 p= 0.02
aAssessed through Bayley-III or HINES.
*Chi-square (Fisher’s exact t-test used when cell values equal zero).
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once in each assay category, although blood specimens were
obtained more than once in over 1/3 of children. Only one patient
tested positive twice on a later time point by the same diagnostic
assay (Zika IgM). Among children who had repeated testing at
later time points in the first year of life or beyond, the over-
whelming trend was for patients to remain negative or switch
from positive to negative results (Table 3). Nevertheless, two
children went from negative to positive results by serum assays
and three children had positive results in urine by PCR after two
previous negative assays.
Concordance of laboratory results. Supplementary Table 1
depicts the different diagnostic assay combinations and con-
cordance between different assays before or after 90 days of life.
The majority of children (82.3%) had two or three concurrent
diagnostic assays at their first visit. Over all time points, IgM
results were concordant with serum and/or urine PCR results
52.3% of the time, with a sensitivity of 65.5% and a specificity of
39.6% (Supplementary Table 1). Concordance up to 90 days of
age was 52% with a sensitivity of 61.5% and a specificity of 37.1%.
Beyond age 3 months concordance for IgM and PCR assays
was 39%, sensitivity 31.5% and specificity 35.7%. Concordance
between IgM and serum PCR results was higher, 61% for all
assays performed, while concordance between serum and urine
PCR results was 55% at all time points.
Clinical assessments. Among the 130 children who were tested
for ZIKV (Table 4), 113 (86%) had brain imaging, with 13% (n=
14) demonstrating structural brain abnormalities (8 cases of
microcephaly and 6 others with severe brain abnormalities).
Complete eye exams were performed in 109 children in this
cohort (83.8%); 6 children (5.5%) had abnormal eye findings.
Ninety-one children (70%) had hearing assessments with 11
abnormal results (12.1%). Twenty-five children were noted to
have grossly abnormal neurologic exams in the first six months of
life (19%). Ten children (7.7 %) were born small for gestational
age reflecting in utero growth restriction. Neurodevelopmental
evaluations performed after 1 year of age demonstrated that 17 of
129 children (13.2%) had severe developmental delay, 14 scored
below 2 SD in one or more Bayley-III domains and 3 were
abnormal by the HINES assessment. When all parameters were
combined, 45 of 130 children (35%) had an abnormal finding in
one or more of these clinical or neurodevelopmental assessments.
Supplementary Table 2 provides detailed clinical data on children
undergoing Bayley-III evaluations.
Laboratory confirmed ZIKV infection and clinical outcomes.
No statistical associations were identified between abnormal
infant findings and positive ZIKV assay results, except for
trimester of maternal infection. Infants born to mothers who
contracted infection in the first trimester of pregnancy were more
likely to have positive ZIKV PCR or IgM results (78%) as com-
pared with those infected in the second (64%) or third trimesters
(48%), p= 0.04 (Table 4). In addition, infants who were diag-
nosed by IgM in the first 90 days of life tended to have mothers
who were infected earlier in gestation (median 14 weeks) than
those diagnosed by IgM after 90 days of life (median 22 weeks),
p < 0.01, as seen in Fig. 2. The median week of infection during
gestation did not differ between infants diagnosed by PCR in
blood or urine before or after 90 days of age (median 18 weeks for
both groups), p= 0.8470.
Although no statistical association was identified between
clinical abnormalities and a positive ZIKV test result (potentially






















Fig. 1 Timing of positive and negative ZIKV laboratory results over time by age. The figure reflects the number of assays performed in each assay
category in specimens collected from 130 children. There were 161 serum specimens run for ZIKV PCR and ZIKV IgM and 85 urine specimens run for ZIKV
PCR. The vertical line in the box represents the median, the box the interquartile range (10–90% of the data), and the whiskers the 95% confidence
interval. The figure represents all the assays performed, not the number of children. All IgM assays were run once and in duplicate and all PCR assays were
run once in triplicate. Children can be represented more than once. Error bars represent the standard deviation.
Table 2 ZIKV vertical transmission by age and assay type.
No. of children Positive %
Tested within the first
3 months of age
94 (72%) 66 70%
PCR serum 76 (81%) 30 39%
IgM 75 (80%) 29 39%
PCR urine 54 (57%) 26 48%
First tested after
3 months of agea
36 (28%) 18 50%
PCR serum 33 (92%) 7 21%
IgM 36 (100%) 7 19%
PCR urine 19 (53%) 8 42%
Tested after
3 months of age
78 (60%) 26 33%
PCR serum 62 (79%) 9 15%
IgM 65 (83%) 13 20%
PCR urine 23 (29%) 10 43%
All time points 130 (100%) 84 65%
PCR serum 109 (84%) 38 35%
IgM 112 (86%) 41 37%
PCR urine 73 (56%) 36 49%
aNinety-four children had their first laboratory test for ZIKV infection within 90 days of age; 36
children had their first assay performed after 90 days of age. Some children had one laboratory
assay performed prior to 90 days of age and a subsequent laboratory assay performed post
90 days of age. Any children in this situation would be counted in the table as tested prior to
90 days of age. If there was repeat testing after 90 days of age children are also counted in that
category for that specific assay, i.e., the number of assays does not reflect the number of
children, as some children had more than one assay.
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because of the relatively small numbers in each category), we saw
a tendency for specific abnormalities to cluster among children
with positive results. Five of six infants with abnormal eye exams
(83%), 11 of 14 with structural brain abnormalities (92%), and 10
of 11 with hearing deficits (91%) had a positive diagnostic assay
for ZIKV infection. However, this clustering was not as clearly
noted in children with other clinical findings such as develop-
mental delay (12 of 17, or 71%), abnormal neurologic exams (16
of 25, 64%), or who were small for gestational age (6 of 10, 60%).
None of these findings, however, achieved statistical significance
as noted in Table 3. Overall, 35% of the 130 children tested for
ZIKV infection had at least one abnormal finding as seen in
Table 3 which means the majority of the cohort (65%) had a
normal outcome. Any positive laboratory test was found in 29 of
45 children (64%) with abnormal findings. Conversely, 55 of
85 children with no abnormalities (65%) also tested positive
for ZIKV, demonstrating that a positive ZIKV test result was
found in 2/3 of children with either normal or abnormal clinical
findings.
Discussion
Laboratory confirmation of ZIKV infection is challenging due to
the short window of viremia and viruria enabling PCR detection,
and also because of the serologic cross-reactivity between Zika
and dengue viruses. In prenatally exposed children, a laboratory
diagnosis of ZIKV infection is even more challenging. The
duration of ZIKV viremia and viruria in congenitally infected
children is unknown, and it is unclear if infants infected very





All infants n % n % p-Value
All infants 130 84 65% 46 35%
Infants with abnormal findingsa 45 29 64% 16 36% 0.98
Infants with no abnormal findingsa 85 55 65% 30 35%
Brain Imaging 113 74 65% 39 35% 0.37
Structural abnormalities 14 11 79% 3 21%
Fundoscopy 109 68 62% 41 38% 0.41
Abnormal 6 5 83% 1 17%
Hearing Assessment 91 60 66% 31 34% 0.09
Abnormal 11 10 91% 1 9%
Neurologic exam 130 84 65% 46 35% 0.94
Abnormal 25 16 64% 9 36%
Gestational age assessment 130 84 65% 46 35% 0.74
Small for gestational age 10 6 60% 4 4%
Neurodevelopment 129 83 64% 46 36% 0.76
Abnormal Bayley-III or HINES 17 12 71% 5 29%
Gestational Trimester of Infection 130 84 65% 46 35%
First 40 31 78% 9 23% 0.04
Second 61 39 64% 22 36%
Third 29 14 48% 15 52%
Pearson’s chi-square with Yates’ continuity correction was used unless expected cell count was <5, then Fisher’s exact test was used.
aIncludes abnormal hearing, eye, gestational age size assessment, neurodevelopment, neurological exam, or structural brain abnormality.
Table 3 Frequency of Zika testing (n= 407 in 130 children).








Serum Zika RT-PCRa 109
Once 67 61.5% 47 20
Two time points 34 31.2% 21 0 11 2
Three time points 6 5.5% 3 0 3 0
Four time points 2 1.8% 0 0 1 1
Zika IgM Mac Elisab 112
Once 72 64.3% 52 20
Two time points 32 28.6% 17 1 12 2
Three time points 7 6.3% 2 0 2 3
Four time points 1 0.9% 0 0 0 1
Urine Zika RT-PCRc 73
Once 64 87.7% 34 30
Two time points 6 8.2% 3 0 3 0
Three time points 3 4.1% 0 0 0 3
aNumber of serum PCR tests (n= 161).
bNumber of Zika IgM Mac Elisa (n= 161).
cNumber of urine Zika RT-PCR (n= 85).
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early during intrauterine life have detectable virus at birth, as the
duration of viral shedding from intrauterine infection has not
been described. In addition, it is unclear if viral presence in blood
and/or urine in congenitally infected children is constant or
intermittent. It is unknown whether all children infected with
ZIKV in utero form adequate antibody responses easily detectable
by IgM assays. For example, experience from other congenital
infections (such as rubella and CMV) tells us that IgM assays are
suboptimal for diagnosis of viruses that affect T and B cell
function. Nevertheless, IgM does not cross the placenta, so we
therefore surmise that positive serologic results would reflect an
infant’s prior exposure to the virus. In the present cohort, cross-
reactivity with dengue virus would be unlikely, as at the time
infant specimens were obtained in Rio de Janeiro (2105–2017)
there was absent to minimal circulation of dengue viruses.
The prospective nature of the cohort, with infants followed
from the time of maternal infection, through birth, and onward
allows us a unique opportunity for evaluation of laboratory
confirmed ZIKV congenital infection rates. Sixty-five percent of
children in our cohort had laboratory evidence of ZIKV infection,
including a large proportion of children who were infected in the
first trimester of pregnancy (78%). Interestingly, having a positive
ZIKV laboratory result did not necessarily correlate with infant
outcomes; this could be due to limitations of the present sample
size or a real phenomenon. What we can conclude from our study
is that ZIKV testing of infants does not necessarily correlate with
clinical findings, particularly in asymptomatic children. Anec-
dotally, in our cohort and that of other Zika cohorts in Brazil,
there were symptomatic children tested in the first 48 h of life
who did not have detectable virus in either blood or urine.
Potentially these children were infected so early during pregnancy
that viral infection is gone by the time of birth and only the
sequelae of infection is present. This is noted in other congenital
infections such as congenital varicella syndrome12. If infection is
later in pregnancy, viral shedding may be more frequently seen,
but the teratogenic sequelae will not be as obvious as the devel-
opment of the neurologic system in the first 12 weeks of gesta-
tional age is past. So viral detection may not clearly correlate with
the presence of clinical findings over time. This phenomenon is
also seen in some children with congenital CMV13. Children who
acquire rubella after 20 weeks of gestation also do not have
findings of congenital rubella syndrome14. The high rate of
positive laboratory results demonstrating infant ZIKV infection
cannot be attributable to a high number of symptomatic children
in the cohort. Eighty-five of 130 children in the study (65%) did
not have any abnormal clinical manifestations at their last med-
ical visit and did not have below average neurodevelopmental
evaluations between ages 2 to 3 years. An equal proportion of
children with both normal and abnormal findings tested positive
(64% and 65%, respectively). We conclude that ZIKV has a very
high in utero transmission rate but laboratory confirmed ZIKV
infection in an infant did not equate to the presence of severe
congenital abnormalities in our cohort.
The transmission rate reported in our study is considerably
higher than the transmission rate of 26% reported by colleagues
in the French Guiana Zika infant cohort15. In that study, ZIKV-
exposed children were clinically evaluated and tested for ZIKV in
the first 7 days of life. Because the degree of intermittent viral
shedding in the blood and urine in ZIKV infected infants has not
been well characterized, testing for ZIKV over a longer period of
time during infancy likely enhances detection of positive results.
One study of pregnant women returning from epidemic areas to
New York evaluated infant diagnosis around the time of birth,
however, the majority of maternal cases were suspected rather
than PCR-confirmed infections, with a 7% vertical transmission
rate at birth for ZIKV infection reported in that study16. Differ-
ences in study design (retrospective versus prospective, follow-up
time, sampling, study population and definitions of infection, i.e.,
confirmed versus suspected) make it difficult to compare results
across different studies.
Our specimens were collected and patients were recruited
during the ZIKV epidemic, before there were any guidelines for
ZIKV diagnostic evaluation of infants, including current CDC
guidelines17. One could argue that the large number of positives
could result from postnatal exposure to ZIKV. However, we
should consider that all children in the present study had PCR-
confirmed ZIKV in utero exposure, so they were all at high risk of
contracting the virus. This differs significantly from scenarios in
which the maternal diagnosis of Zika infection is unconfirmed
and infant exposure status is unknown. Because ZIKV diagnostics
in infants was considered investigational at the time, we did not
collect specimens from infants born early on in the epidemic,
which is when ZIKV was still circulating, which is a study
limitation, as collection of early specimens in all children
would have been ideal. In May 2016 we saw a dramatic decline in
ZIKV circulation in Rio de Janeiro, which coincided with a
















































Fig. 2 Infant positive PCR and IgM results by infant age and maternal gestational age of infection. Panel (a) depicts positive ZIKV PCR results in serum
or urine for unique children. Before 90 days of age, 45 children had positive PCR results. After 90 days of age, 17 children had positive PCR results. The
difference in distribution of positive PCR results between both age groups was not statistically significant, p= 0.87. Panel (b) depicts positive ZIKV IgM
results. Before 90 days of infant age, 29 infants had positive results. After 90 days of age, 13 children had positive IgM results. The difference in distribution
of positive IgM results between both age groups was statistically significant, p= 0.03. The statistical test used for comparison was a two-sided hypothesis
Student T-test at the alpha 0.05 level. There were no adjustments for multiple comparisons. Error bars represent the standard deviation.
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Chikungunya outbreak18,19. For this reason, it is unlikely that the
tested group of infants had a high chance of acquiring postnatal
ZIKV infection, as by the time most of them were born, the virus
was no longer circulating in Rio de Janeiro. We nevertheless did
observe a much higher frequency of positive results in the first
3 months of life, reflecting a short window for detection of
congenitally acquired ZIKV infection, including a short period of
ZIKV IgM positivity, a finding that has been reported in adults
following ZIKV infection20.
One of our study limitations is that we did not perform
sequential testing of all infants at regular time points. We were able
to perform PCR immediately following specimen collection for
most infant serum and urine specimens which contributes to a
greater sensitivity of the assay, as PCR identification of ZIKV tends
to greatly diminish with freezing and thawing of specimens21.
Nevertheless, because sequential, methodical testing at regular time
points was not possible for many children, we cannot ascertain that
the ones with negative results were true negatives. In addition, we
did not have as many early postnatal specimens available for testing
to assure ascertainment of infection in infants born early on in the
epidemic (when IRB approval was pending) and this is a study
limitation. We certainly could have missed the window of positivity
for a number of children who tested PCR negative for ZIKV sub-
sequently. Another study limitation is that we did not have a
control group of ZIKV unexposed children of the same age and
from the same location for comparison of clinical neurodevelop-
mental outcomes and serial laboratory testing. Because ZIKV
infection can be asymptomatic during pregnancy, we were unable
to recruit an equal number of children in parallel in whom we could
effectively rule out past maternal ZIKV infection during gestation.
In Rio de Janeiro during the epidemic, any pregnant woman could
have silent ZIKV infection, while infants born without clinical
features of congenital Zika would not be identified as having in
utero exposure. Therefore, we could not rule out that control
children were in truth controls. It is also unclear if all children
exposed to ZIKV are capable of developing a robust IgM response.
We know that in other congenital infections such as rubella and
CMV, there can be a significant delay in the development of IgM
antibodies13,14. In this sense, we believe the 65% ZIKV transmission
rate is likely an underestimate.
We found a statistically significant association between earlier
maternal infection in pregnancy and ZIKV infant infection,
which demonstrates that transmission events are more likely
when women are infected earlier in pregnancy. Nevertheless,
close to 50% of women infected in the third trimester also had
infants with positive results, which underscores that ZIKV is
highly transmissible throughout the entire gestational period. We
also observed that women infected earlier in pregnancy tended to
have infants with positive IgM results earlier in life. Conversely,
women infected later in pregnancy tended to have infants whose
IgM results were positive beyond 90 days of life. One caveat is
that all women in our cohort were symptomatic. In a prior
analysis we did not find any associations between the magnitude
of maternal symptoms and infant clinical findings22. In addition,
congenital Zika syndrome has been described in children of
asymptomatic women8. Potentially women with symptomatic
ZIKV infection could have children with more clinical findings,
however, this hypothesis has not yet been confirmed. Future
research to determine factors related to transplacental transmis-
sion of the virus over gestation is needed.
As is the case with most congenitally acquired viral infections,
such as CMV, rubella, or HIV, PCR of urine and serum (com-
bined) was superior in diagnosing ZIKV infection as compared to
serology alone. Urine PCR appeared to be most sensitive yielding
the highest proportion of positive results23. As urine specimens
were collected in 56% of the children in the cohort, higher rates of
vertical transmission might have been observed if more urine
specimens were obtained. IgM and serum PCR tended to provide
similar rates of positivity. Nevertheless, because we did not have
sequential, simultaneous testing of specimens at regular intervals
by all assays, comparison between types of specimens and fre-
quency of positive and negative results should be interpreted with
caution.
Interestingly, a small number of children had positive PCR
results after 200 days of life. One child developed positive IgM
results during the same time period. Although we cannot rule out
postnatal infection, because ZIKV stopped circulating in Rio de
Janeiro by that time, postnatal infection seems unlikely. ZIKV
could be shed intermittently in the blood or urine, similarly to
congenital CMV or congenital rubella13,14. These children had
negative test results before, which would suggest intermittent
shedding. A delayed IgM response could be present in con-
genitally acquired ZIKV infection, explaining late positive IgM
results. Intermittent and long-term shedding of ZIKV in the urine
is very concerning for the presence of viral reservoirs with low-
level replication that persist in some neonates.
A negative laboratory test result for ZIKV infection early in life
will not rule out congenitally acquired infection because in many
cases the narrow window period for testing may be missed. A
positive result, however, particularly in our setting where women
had PCR-confirmed infection is helpful in ascertaining infection
versus exposure. Current CDC testing guidelines recommend test-
ing of infants as early as possible, preferably within the first few days
after birth13, although according to our results testing specimens
within the first few weeks up to 3 months of age might still be
useful. Distinguishing between congenital, perinatal, and postnatal
infection is difficult in infants living in endemic areas who are not
tested soon after birth. Nevertheless, one has to take into account
the epidemiologic surveillance data to ascertain if circulation of the
virus is ongoing when interpreting results. There are no studies to
date, to our knowledge, reporting data on sequential infant testing
following PCR-confirmed ZIKV antenatal exposure. Whether the
pattern of viral shedding in antenatally infected infants is persistent
or intermittent is unknown.
In summary, approximately 2/3 of children tested for ZIKV
infection in our prospective cohort were positive, which means
ZIKV in utero transmission is very frequent. Having a positive test
result is not necessarily associated with a bad outcome, but there is
an association with earlier maternal infection in pregnancy. Given
the high transmission rate and the fact that a negative laboratory
assay for ZIKV may not rule out infection, all infants with docu-
mented or potential antenatal ZIKV exposure should be followed
long term. Intermittent viral shedding in the urine occurs in a small
number of infants and suggests the presence of viral reservoirs. We
have seen that a normal early infant assessment may not necessarily
guarantee normal neurodevelopment or absence of sensory dys-
function5. As laboratory diagnostic testing does not seem to predict
infant outcomes, close follow-up of all children with antenatal
ZIKV exposure should be the norm.
Methods
Study population. The study population was comprised by infants born to women
enrolled in a longitudinal cohort of confirmed ZIKV infection during pregnancy2,
for whom postnatal samples of blood and/or urine were collected for ZIKV
laboratory diagnosis. Gestational age of infection was estimated based on the day
the pregnant woman first presented with the rash due to ZIKV infection confirmed
by PCR in blood or urine. All children were followed at the Fundação Oswaldo
Cruz (Fiocruz) in Rio de Janeiro and were enrolled from December 2015 to
December 2016.
ZIKV PCR detection. Infant serum and urine specimens were obtained following
parental signed informed consent. Serum was collected by standard phlebotomy
procedures and processed immediately for PCR while additional aliquots were
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stored at −80 °C for subsequent testing for Zika IgM. Urine specimens collected by
bagged urine collection, spun in a refrigerated centrifuge for 10 min at 700 × g, and
the supernatant was aliquoted and processed immediately for PCR. Both serum
and urine specimens were tested by qRT-PCR amplification assay for ZIKV in
triplicate using the TaqMan probe (Applied Biosystems) for detection and absolute
quantification of ZIKV2,11. The following primers were used [Primer Genome
Position Sequence (5′→ 3′)]:
ZIKV 1086 1086–1102 CCGCTGCCCAACACAAG.
ZIKV 1162c 1162–1139 CCACTAACGTTCTTTTGCAGACAT.
ZIKV 1107-FAM 1107–1137 AGCCTACCTTGACAAGCAGTCAGACACTCAA.
Laboratory testing sites included the research laboratory of the Instituto
Fernandes Figueira Hospital (IFF) and the Laboratory of Molecular Biology of
Flaviviruses, Fiocruz.
ZIKV IgM detection. ZIKV serologic testing of infants was performed in duplicate
serum aliquots using IgM antibody capture Zika MAC-ELISA from the Centers for
Disease Control and Prevention (CDC, Fort Collins, CO, EUA) according to
manufacturer instructions24. All serum samples were diluted at 1:400 in wash
buffer and conjugate antibodies were diluted at 1:2500 in blocking buffer.
Pediatric outcomes. Pediatric outcomes (normal versus abnormal) were deter-
mined based on specific clinical findings.
Early infant findings. Were defined based on the presence of any of the following
medical findings in the first 3 months of life: (1) Microcephaly (MC) defined as
head circumference Z-score <−2 (moderate) and <−3 (severe)25; (2) small for
gestational age (SGA) at birth based on sex-specific curves by Intergrowth-2126;
(3) abnormal eye findings following a complete exam with funduscopic
evaluation performed by pediatric ophthalmologists27–30; (4) abnormal
hearing assessments evaluated through brainstem evoked response audiometry
(BERA)3,4; (5) very abnormal neurological exam, with a constellation of
findings on repeated physical examination including a combination of hyper-
or hypotonia, clonus, contractures/arthrogryposis, seizures, continuous irrit-
ability (inconsolable crying)2–6; abnormal finding on neuroimaging through
transfontanelle ultrasounds, and/or computerized tomography, and/or magnetic
resonance imaging with identification of structural brain abnormalities (i.e.,
disorders altering normal brain morphology)2,31.
Later neurodevelopmental findings. Defined as abnormal based on the presence of
any of the following beyond 6 months of life: (1) Severe developmental delay with a
Bayley-III Score32 under −2SD (<70) in any functional domain (cognitive, lan-
guage or motor)3,4; (2) abnormal time to achievement of developmental stages
through the Hammersmith Infant Neurological Examination scheme (HINES),
evaluating neurological exam, motor function and state of behavior3,4.
Statistical analysis. Chi-square tests were used to examine differences in cate-
gorical covariates between groups. When cell counts were <5 infants for any group,
Fisher-exact tests were performed. Positive and negative predictive values were
calculated for below normal development based on clinical outcomes. Associations
between gestational age at infection and clinical outcomes including microcephaly,
structural image abnormalities, hearing or eye abnormalities, development, or
ZIKV laboratory results were explored by Pearson’s chi-square. Analyses were
conducted using the statistical package R (R version 3.0.1, The R Foundation for
Statistical Computing, www.r-project.org).
Study oversight. The study was approved by the institutional review boards of the
Fundação Oswaldo Cruz (Fiocruz) and the University of California, Los Angeles.
Parents or guardians provided written informed consent.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the article and its Supplementary Information files, or are available from the
authors upon request. Source data are provided with this paper.
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